中华航海医学与高气压医学杂志
中華航海醫學與高氣壓醫學雜誌
중화항해의학여고기압의학잡지
CHINESE JOURNAL OF NAUTICAL MEDICINE AND HYPERBARIC MEDICINE
2013年
3期
178-181
,共4页
高压氧%颅脑损伤%巨噬细胞移动抑制因子%脂肪炎症因子
高壓氧%顱腦損傷%巨噬細胞移動抑製因子%脂肪炎癥因子
고압양%로뇌손상%거서세포이동억제인자%지방염증인자
Hyperbaric oxygen%Severe craniocerebral injury%Macrophage migration-inhibitory factor%Apelin
目的 探讨重型颅脑损伤患者高压氧(hyperbaric oxygen,HBO)治疗前后,外周血巨噬细胞移动抑制因子(MIF)和脂肪炎症因子(Apelin)的水平变化及其与HBO治疗效果及预后的关系.方法 选择2010年3月至2011年3月由我院神经外科确诊并收治的120例颅脑损伤患者,经患者知情同意,并签署知情同意书后随机分为HBO组和常规治疗组,每组60例.HBO组行HBO+常规治疗,常规治疗组仅单纯常规治疗.选择60名健康体检者为正常对照组.3组分别于治疗前用哥拉斯哥评分(Glasgow coma scale,GCS)对患者进行评定,采用酶联免疫(ELISA)法检测血清MIF和Apelin含量.结果 HBO组和常规治疗组治疗前MIF和Apelin差异无统计学意义(t=1.05、1.02,P均＞0.05),但与正常对照组比较差异均有统计学意义(MIF:t=16.23、16.14; Apelin:17.48、17.53;均P＜0.01).治疗1个疗程后,HBO组[(17.73±2.25) μg/L、(112.72±20.35) ng/L]和常规治疗组[(26.17±2.38) μg/L、(182.14±21.47) ng/L] MIF和Apelin水平均比治疗前[HBO组:(32.63±2.79)μg/L、(246.65±29.62)ng/L;常规治疗组:(32.42±2.81)μg/L、(246.65±29.62) ng/L]有所下降(MIF:t=12.49、8.63,Apelin:12.73、8.24,；均P＜0.05)；治疗3个疗程后,HBO组的MIF和Apelin水平逐渐接近正常对照组(t=1.18、1.23,均P＞0.05),而常规治疗组MIF和Apelin水平均高于HBO组和正常对照组(MIF:t =8.23、8.39,Apelin:8.21,8.37;均P＜0.05).结论 HBO能影响颅脑损伤患者MIF和Apelin水平,提示检测患者外周血MIF和Apelin含量,可作为观察HBO治疗效果的辅助指标.
目的 探討重型顱腦損傷患者高壓氧(hyperbaric oxygen,HBO)治療前後,外週血巨噬細胞移動抑製因子(MIF)和脂肪炎癥因子(Apelin)的水平變化及其與HBO治療效果及預後的關繫.方法 選擇2010年3月至2011年3月由我院神經外科確診併收治的120例顱腦損傷患者,經患者知情同意,併籤署知情同意書後隨機分為HBO組和常規治療組,每組60例.HBO組行HBO+常規治療,常規治療組僅單純常規治療.選擇60名健康體檢者為正常對照組.3組分彆于治療前用哥拉斯哥評分(Glasgow coma scale,GCS)對患者進行評定,採用酶聯免疫(ELISA)法檢測血清MIF和Apelin含量.結果 HBO組和常規治療組治療前MIF和Apelin差異無統計學意義(t=1.05、1.02,P均＞0.05),但與正常對照組比較差異均有統計學意義(MIF:t=16.23、16.14; Apelin:17.48、17.53;均P＜0.01).治療1箇療程後,HBO組[(17.73±2.25) μg/L、(112.72±20.35) ng/L]和常規治療組[(26.17±2.38) μg/L、(182.14±21.47) ng/L] MIF和Apelin水平均比治療前[HBO組:(32.63±2.79)μg/L、(246.65±29.62)ng/L;常規治療組:(32.42±2.81)μg/L、(246.65±29.62) ng/L]有所下降(MIF:t=12.49、8.63,Apelin:12.73、8.24,；均P＜0.05)；治療3箇療程後,HBO組的MIF和Apelin水平逐漸接近正常對照組(t=1.18、1.23,均P＞0.05),而常規治療組MIF和Apelin水平均高于HBO組和正常對照組(MIF:t =8.23、8.39,Apelin:8.21,8.37;均P＜0.05).結論 HBO能影響顱腦損傷患者MIF和Apelin水平,提示檢測患者外週血MIF和Apelin含量,可作為觀察HBO治療效果的輔助指標.
목적 탐토중형로뇌손상환자고압양(hyperbaric oxygen,HBO)치료전후,외주혈거서세포이동억제인자(MIF)화지방염증인자(Apelin)적수평변화급기여HBO치료효과급예후적관계.방법 선택2010년3월지2011년3월유아원신경외과학진병수치적120례로뇌손상환자,경환자지정동의,병첨서지정동의서후수궤분위HBO조화상규치료조,매조60례.HBO조행HBO+상규치료,상규치료조부단순상규치료.선택60명건강체검자위정상대조조.3조분별우치료전용가랍사가평분(Glasgow coma scale,GCS)대환자진행평정,채용매련면역(ELISA)법검측혈청MIF화Apelin함량.결과 HBO조화상규치료조치료전MIF화Apelin차이무통계학의의(t=1.05、1.02,P균＞0.05),단여정상대조조비교차이균유통계학의의(MIF:t=16.23、16.14; Apelin:17.48、17.53;균P＜0.01).치료1개료정후,HBO조[(17.73±2.25) μg/L、(112.72±20.35) ng/L]화상규치료조[(26.17±2.38) μg/L、(182.14±21.47) ng/L] MIF화Apelin수평균비치료전[HBO조:(32.63±2.79)μg/L、(246.65±29.62)ng/L;상규치료조:(32.42±2.81)μg/L、(246.65±29.62) ng/L]유소하강(MIF:t=12.49、8.63,Apelin:12.73、8.24,；균P＜0.05)；치료3개료정후,HBO조적MIF화Apelin수평축점접근정상대조조(t=1.18、1.23,균P＞0.05),이상규치료조MIF화Apelin수평균고우HBO조화정상대조조(MIF:t =8.23、8.39,Apelin:8.21,8.37;균P＜0.05).결론 HBO능영향로뇌손상환자MIF화Apelin수평,제시검측환자외주혈MIF화Apelin함량,가작위관찰HBO치료효과적보조지표.
Objective To study changes in serum macrophage migration-inhibitory factor(MIF) and Apelin and the relationship between hyperbaric oxygen (HBO) and its prognosis,following pre and post HBO therapy of patients with severe craniocerebral injury.Methods One hundred and twenty patients were chosen as subjects diagnosed and admitted into the Neurosurgical Department of our hospital from March 2010 to March 2011.With the knowledge and consent of the patients and following the signing of the letter of agreement,the patients were divided into the HBO group and the routine treatment group,each consisting of 60 patients.The HBO group was given HBO therapy + routine treatment,while the routine treatment group was only given routine treatment,and another 60 people who had routine physical check-ups served as the control group.The patients were assessed with Glasgow Outcome Scale (GOS) both before and after treatment.Levels of MIF and Apelin in the serum were detected with ELISA.Results No statistical significance could be noticed in the serum levels of MIF and Apelin detected both before and after treatment,when comparisons were made between the HBO group and the routine treatment group (t =1.05,1.02 ; P ＞ 0.05).However,statistical significance could be noted,when compared with the control group (MIF:t =16.23,16.14 ; Apelin:t =17.48,17.53)(P ＜ 0.01).After one course of treatment,levels of MIF and Apelin for the HBO group [(17.73 ±2.25)μg/L,(112.72 ±20.35)ng/L] and the routine treatment group [(26.17 ±2.38) μg/L,(182.14 ± 21.47) ng/L] were all lower than those before treatment [HBO group:(32.63 ± 2.79) μg/L,(246.65 ± 29.62) ng/L; the routine treatment group:(32.42 ± 2.81) μg/L,(246.65 ± 29.62) ng/L] (MIF:t =12.49,8.63 ; Apelin:t =12.73,8.24,P ＜ 0.05).After 3 courses of treatment,levels of MIF and Apelin gradually approached the normal values of the normal control group (t =1.18,1.23) (P ＞ 0.05),while the levels of MIF and Apelin for the routine treatment group were all higher than those of the control group(MIF:t =8.23,8.39; Apelin:t=8.21,8.37)(P＜0.05).Conclusions HBO seemed to affect the serum levels of MIF and Apelin in patients with severe craniocerebral injury,indicating that the levels of MIF and Apelin detected in the peripheral blood might serve as important adjuvant markers for the observation on the effect of HBO therapy.
